Clofarabine
- Generic Name
- Clofarabine
- Brand Names
- Clolar, Evoltra
- Drug Type
- Small Molecule
- Chemical Formula
- C10H11ClFN5O3
- CAS Number
- 123318-82-1
- Unique Ingredient Identifier
- 762RDY0Y2H
- Background
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...
- Indication
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
- Associated Conditions
- Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
- Associated Therapies
- -
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2020-04-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT00857389
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
- First Posted Date
- 2009-02-27
- Last Posted Date
- 2018-02-15
- Target Recruit Count
- 35
- Registration Number
- NCT00852709
- Locations
- 🇺🇸
University of Colorado Health Sciences Center and The Children's Hospital, Aurora, Colorado, United States
🇺🇸Pediatrix Hematology/Oncology University of Florida College of Medicine, Gainesville, Florida, United States
🇺🇸M.D. Anderson Comprehensive Cancer Center, Houston, Texas, United States
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Myelodysplastic Syndrome With Isolated Del(5q)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Previously Treated Myelodysplastic SyndromesRecurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 35
- Registration Number
- NCT00839982
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia
- Conditions
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2012-07-20
- Target Recruit Count
- 114
- Registration Number
- NCT00838240
- Locations
- 🇧🇪
Institut Jules Bordet, Brussel, Belgium
🇮🇹Azienda Ospedallera Universitaria - Policlinico Tor Vergata, Roma, Italy
🇮🇹Univesita Degli Studi "La Sapienza", Roma, Italy
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
- First Posted Date
- 2009-01-16
- Last Posted Date
- 2017-01-02
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT00824135
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- First Posted Date
- 2008-12-24
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 21
- Registration Number
- NCT00814164
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2008-10-23
- Last Posted Date
- 2016-07-14
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 122
- Registration Number
- NCT00778375
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2017-11-09
- Target Recruit Count
- 60
- Registration Number
- NCT00775593
- Locations
- 🇮🇹
Policlinico G. B. Rossi - Borgo Roma, Verona, Italy
🇮🇹Ospedale S. Eugenio, Roma, Italy
🇮🇹S.C. di Ematologia e Trapianti - I.F.O. Istituto Nazionale Tumori Regina Elena, Roma, Italy
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)
- First Posted Date
- 2008-09-10
- Last Posted Date
- 2015-05-21
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 2
- Registration Number
- NCT00750334
- Locations
- 🇺🇸
Malignant Hematology Administration, H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Division of Hematology Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Cancer Care Centers of South Texas, San Antonio, Texas, United States
Oral Clofarabine for Acute Myeloid Leukemia
- First Posted Date
- 2008-08-04
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 25
- Registration Number
- NCT00727766
- Locations
- 🇺🇸
Washington University, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.